ZCCHC8: A Potential Drug Target for Fibrosis (G55596)

Target Name: ZCCHC8

NCBI ID: G55596

ZCCHC8

ZCCHC8: A Potential Drug Target for Fibrosis

ZCCHC8 (PFBMFT5) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-protein binding proteins (SPPs), which are a type of transmembrane protein that can interact with RNA molecules. ZCCHC8 has been shown to play a role in a variety of physiological processes, including cell signaling, inflammation, and fibrosis.

One of the unique features of ZCCHC8 is its ability to interact with small RNA molecules, such as microRNAs (miRNAs) and small interfering RNA (siRNA). These interactions can alter the stability and translation efficiency of these molecules, which can have a significant impact on gene expression and cellular processes.

In addition to its role in cell signaling and RNA homeostasis, ZCCHC8 has also been shown to be involved in the regulation of fibrosis. Fibrosis is a complex process that involves the activation and proliferation of fibroblasts, which are cells that produce collagen, a protein that is involved in the development and maintenance of tissue extensibility and repair.

ZCCHC8 has been shown to promote the growth and proliferation of fibroblasts, and it has been proposed as a potential drug target for the treatment of fibrosis. One reason for its potential as a drug target is its ability to interact with multiple signaling pathways that are involved in fibrosis, including the TGF-β pathway and the Wnt pathway.

The TGF-β pathway is a well-established pathway that is involved in the regulation of cell growth, differentiation, and survival. Fibroblasts are a type of cell that are highly dependent on the TGF-β pathway, and changes in this pathway have been implicated in the development and progression of fibrosis.

ZCCHC8 has been shown to regulate the activity of the TGF-β pathway by interacting with its downstream target, Smad4. Smad4 is a key transcription factor that is involved in the regulation of gene expression and has been shown to play a role in the development of fibrosis.

The Wnt pathway is another signaling pathway that is involved in the regulation of cell growth and development. Fibroblasts are a type of cell that are highly dependent on the Wnt pathway, and changes in this pathway have been implicated in the development and progression of fibrosis.

ZCCHC8 has been shown to regulate the activity of the Wnt pathway by interacting with its downstream target, Fz1. Fz1 is a transcription factor that is involved in the regulation of gene expression and has been shown to play a role in the development of fibrosis.

In conclusion, ZCCHC8 is a protein that is involved in a variety of physiological processes, including cell signaling, inflammation, and fibrosis. Its ability to interact with small RNA molecules, such as miRNAs and siRNAs, makes it a potential drug target for the treatment of fibrosis. In future studies, further research is needed to determine the exact mechanism of action of ZCCHC8 and its potential as a drug.

Protein Name: Zinc Finger CCHC-type Containing 8

Functions: Scaffolding subunit of the trimeric nuclear exosome targeting (NEXT) complex that is involved in the surveillance and turnover of aberrant transcripts and non-coding RNAs (PubMed:27871484). NEXT functions as an RNA exosome cofactor that directs a subset of non-coding short-lived RNAs for exosomal degradation. May be involved in pre-mRNA splicing (Probable). It is required for 3'-end maturation of telomerase RNA component (TERC), TERC 3'-end targeting to the nuclear RNA exosome, and for telomerase function (PubMed:31488579)

The "ZCCHC8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZCCHC8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets